http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018
-
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
-
Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA for Solriamfetol
-
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
-
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results
-
Jazz Pharmaceuticals (JAZZ) Reports 1st Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide
-
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
-
Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018
-
Jazz Pharmaceuticals (JAZZ) Reports Addition of Vyxeos (daunorubicin & cytarabine) Liposome for Injection by National Comprehensive Cancer Network to Clinical Practice Guidelines in Oncology
-
National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology
-
Jazz Pharmaceuticals (JAZZ) Submits NDA for Solriamfetol for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
-
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
-
Jazz Pharma (JAZZ), Pfenex (PFNX) Enter Hematological Malignancies-Related Licensing Agreement
-
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
-
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
-
Pre-Open Stock Movers 04/13: (RPRX) (ACUR) (MDVN) Higher; (CLVS) (VRX) (S) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 3/30: (MET) (JAZZ) (VRX) (TWTR)

